KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Investing Activities: 2011-2024

Historic Cash from Investing Activities for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$317,000.

  • Esperion Therapeutics' Cash from Investing Activities was N/A to -$167,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $17.2 million, marking a year-over-year change of. This contributed to the annual value of -$317,000 for FY2024, which is 100.75% down from last year.
  • Esperion Therapeutics' Cash from Investing Activities amounted to -$317,000 in FY2024, which was down 100.75% from $42.5 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Cash from Investing Activities ranged from a high of $42.5 million in FY2023 and a low of -$50.5 million during FY2021.
  • For the 3-year period, Esperion Therapeutics' Cash from Investing Activities averaged around $16.8 million, with its median value being $8.1 million (2022).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 336.39% in 2021, then skyrocketed by 424.43% in 2023.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Cash from Investing Activities stood at $21.4 million in 2020, then slumped by 336.39% to -$50.5 million in 2021, then spiked by 116.05% to $8.1 million in 2022, then soared by 424.43% to $42.5 million in 2023, then plummeted by 100.75% to -$317,000 in 2024.